JP2530488B2 - Cosmetics - Google Patents

Cosmetics

Info

Publication number
JP2530488B2
JP2530488B2 JP63265034A JP26503488A JP2530488B2 JP 2530488 B2 JP2530488 B2 JP 2530488B2 JP 63265034 A JP63265034 A JP 63265034A JP 26503488 A JP26503488 A JP 26503488A JP 2530488 B2 JP2530488 B2 JP 2530488B2
Authority
JP
Japan
Prior art keywords
acid
examples
effect
inhibition
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP63265034A
Other languages
Japanese (ja)
Other versions
JPH02111714A (en
Inventor
秀則 松田
俊治 横手
利行 小林
盟 中平
悟 中田
宏明 小西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nonogawa Shoji Ltd
Original Assignee
Nonogawa Shoji Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nonogawa Shoji Ltd filed Critical Nonogawa Shoji Ltd
Priority to JP63265034A priority Critical patent/JP2530488B2/en
Publication of JPH02111714A publication Critical patent/JPH02111714A/en
Application granted granted Critical
Publication of JP2530488B2 publication Critical patent/JP2530488B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26Aluminium; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は抗炎症効果を有する化粧料に関する。TECHNICAL FIELD The present invention relates to a cosmetic having an anti-inflammatory effect.

(従来の技術) カリミョウバンは、タンパク質と結合してこれを凝固
させることで局所収れん作用を有することが知られてい
る。このため化粧料では、アストリンゼントなどの化粧
料、スキントニック、アフターシェーブローション、洗
顔剤、浴剤などに用いられている。
(Prior Art) It is known that potassium alum has a local astringent action by binding to a protein and coagulating it. Therefore, in cosmetics, it is used in cosmetics such as astringent, skin tonics, aftershave lotions, facial cleansers, baths and the like.

酸は、化粧料では主にpH調整に用いられている。 Acids are mainly used for pH adjustment in cosmetics.

(発明が解決しようとする問題点) 化粧料である特定の効果を持たせようとする場合、特
定の薬剤を配合させなくてはいけない。しかし薬剤を配
合することで、皮膚トラブルの原因となったり、ベース
の経時安定性が著しく低下したりすることがある。例え
ば、抗炎症剤としてニキビ用化粧料に配合されるサルフ
ァ剤は、経時的に変臭を起こしたり、ベースの変色を起
こしたりする等の問題があった。
(Problems to be Solved by the Invention) In order to provide a cosmetic with a specific effect, a specific drug must be mixed. However, compounding a drug may cause skin troubles or significantly deteriorate the stability of the base over time. For example, a sulfa drug, which is added to an acne cosmetic as an anti-inflammatory agent, has a problem that it may cause a change in odor or a discoloration of the base over time.

(問題を解決するための手段) 本発明は,カリミョウバンと,マロン酸,クエン酸,
ショウ酸,コハク酸,フマル酸,リンゴ酸,酒石酸,ピ
ロリドンカルボン酸,アスパラギン酸,及びグルタミン
酸のグループから選ばれる1種又は2種以上からなる酸
とを配合してなり, かつ抗菌力,リパーゼ活性阻害,ヒスタミン遊離抑
制,及び抗酸化力を有することを特徴とする抗炎症効果
を有する化粧料にある。
(Means for Solving Problems) The present invention relates to potassium alum, malonic acid, citric acid,
A mixture of one or more acids selected from the group consisting of oxalic acid, succinic acid, fumaric acid, malic acid, tartaric acid, pyrrolidonecarboxylic acid, aspartic acid, and glutamic acid, and having antibacterial activity and lipase activity. It is a cosmetic having an anti-inflammatory effect, which is characterized by having inhibition, histamine release inhibition, and antioxidant power.

本発明で使用するカリミョウバンとは、化学名硫酸ア
ルミニウムカリウムのことである。
The potassium alum used in the present invention has a chemical name of potassium aluminum sulfate.

本発明で使用する酸は,マロン酸,クエン酸,ショウ
酸,コハク酸,フマル酸,リンゴ酸,酒石酸,ピロリド
ンカルボン酸,アスパラギン酸,及びグルタミン酸のグ
ループから選ばれる1種又は2種以上である。
The acid used in the present invention is one or more selected from the group consisting of malonic acid, citric acid, oxalic acid, succinic acid, fumaric acid, malic acid, tartaric acid, pyrrolidonecarboxylic acid, aspartic acid, and glutamic acid. .

本発明で言う抗炎症効果とは、ニキビ、毛包炎(おで
き)、かぶれ、あせも等の吹出物の原因である炎症を抑
える作用のことをいう。ニキビ、かぶれ、毛包炎(おで
き)、あせも等の吹出物は皮膚中での炎症が原因で引き
起こされる。これらの炎症の原因には、いろいろなもの
がある。たとえば、毛包内につまった皮脂がニキビ原因
菌Propionibacterium acnes(以後P.acnes)などの細菌
の産生するリパーゼによって分解され遊離される脂肪酸
の刺激によるものや、黄色ブドウ球菌が毛孔に感染して
化膿するものや、皮膚組織の肥満細胞からヒスタミンが
遊離され毛細血管を拡張して紅斑が生じたり、毛細血管
透過性亢進により血管から血しょう蛋白や水分が組織に
流れ出すという原因により生じるものがある。
The anti-inflammatory effect referred to in the present invention means an action of suppressing inflammation which is the cause of pimples such as acne, folliculitis (burns), rash, and heat rash. Pimples such as acne, rashes, folliculitis (burns), and heat rash are caused by inflammation in the skin. There are various causes of these inflammations. For example, sebum clogged in hair follicles is caused by stimulation of fatty acids that are decomposed and released by lipase produced by bacteria such as Propionibacterium acnes (hereinafter P. acnes) that causes acne, and Staphylococcus aureus infects pores. Some of them are purulent, others are caused by histamine being released from skin tissue mast cells, dilating capillaries to cause erythema, or by causing capillary protein permeability to cause plasma proteins and water to flow from the blood vessels into tissues. .

本発明の化粧料とは、油脂類、ロウ類、炭化水素類、
脂肪酸類、アルコール類、エステル類、アミン・アミド
・金属セッケン、界面活性剤等の油脂加工製品、香料、
ガム質及び水溶性高分子化合物、あるいはビタミン類な
どを基材として製造される加工製品をいう。
The cosmetics of the present invention include oils and fats, waxes, hydrocarbons,
Fatty acid, alcohols, esters, amine / amide / metal soap, processed oils and fats such as surfactants, fragrances,
It refers to processed products manufactured using gums and water-soluble polymer compounds or vitamins as a base material.

これらの基剤を原料として製造される加工製品として
は、化粧水、乳液、クリーム、リップクリーム、口紅、
ファンデーション、香水、オーデコロンなどが挙げられ
る。
Processed products produced using these bases as raw materials include lotions, emulsions, creams, lip balms, lipsticks,
Examples include foundations, perfumes, colognes, etc.

本発明の化粧料に配合するカリミョウバン及び酸の使
用量は、カリミョウバン0.001〜10重量パーセント、酸
0.001〜10重量パーセント配合される。好ましくは、カ
リミョウバン0.01〜5重量パーセント、酸0.01〜5重量
パーセントの割合になるように配合される。
The amount of potassium alum and acid used in the cosmetic of the present invention is 0.001 to 10% by weight of potassium alum and acid.
0.001 to 10 weight percent is blended. Preferably, 0.01 to 5 weight percent potassium alum and 0.01 to 5 weight percent acid are blended.

またカリミョウバン及び酸の添加方法については、予
め水溶液にしておいて製造途中で添加してもよく、作業
性を考えて適宜選択すればよいが、製品中で均一になっ
ていれば良い。
Regarding the method of adding potassium alum and acid, it may be added in the form of an aqueous solution in advance during production, and may be appropriately selected in consideration of workability, but it should be uniform in the product.

(発明の効果) 以下に実験例、実施例を挙げて本発明をさらに具体的
に説明する。本発明は、これにより限定されるものでな
い。なお数値は、特に断わりのないかぎり重量パーセン
トを示す。
(Effects of the Invention) The present invention will be described more specifically below with reference to experimental examples and examples. The present invention is not limited thereby. Numerical values indicate weight percent unless otherwise specified.

本発明の抗炎症効果を有する化粧料について、吹出物
の炎症の原因に注目して、それに対する効果を測定し
た。効果として、抗菌力、リパーゼ活性阻害、ヒスタミ
ン遊離抑制、抗酸化力について試験を行った。また実際
に使用試験を行って、吹出物に対する効果を評価した。
Regarding the cosmetics having an anti-inflammatory effect of the present invention, attention was paid to the cause of inflammation in the pimples, and the effect was measured. As effects, antibacterial activity, inhibition of lipase activity, inhibition of histamine release, and antioxidant activity were tested. In addition, a use test was actually conducted to evaluate the effect on the pimples.

1.抗菌力試験 a.ニキビ原因菌(P.acnes)を用いた方法 試験管に嫌気性菌用ブイヨン培地を秤量し、そこへ試
料及び蒸留水を用い指定濃度になるように調整する。滅
菌後P.acnesの菌液を添加し、37℃で静置培養する。培
養後、試験管の濁りを観察し抗菌力があるかを判定し
た。
1. Antibacterial activity test a. Method using acne-causing bacteria (P. acnes) Weigh the broth medium for anaerobic bacteria in a test tube, and adjust to the specified concentration using the sample and distilled water. After sterilization, add P. acnes bacterial solution and incubate at 37 ℃. After culturing, the turbidity of the test tube was observed to determine whether it had an antibacterial activity.

b.黄色ブドウ球菌を用いた方法 試験管にトリプトソイブイヨンの固型粉体を秤量し、
そこに試料及び蒸留水を用い指定濃度になるように調整
する。滅菌後黄色ブドウ球菌を添加し37℃で静置培養す
る。培養後、試験管の濁りを観察し抗菌力があるかを判
定した。
b. Method using Staphylococcus aureus Weigh the solid powder of tryptosome broth into a test tube,
Adjust to the specified concentration using the sample and distilled water. After sterilization, Staphylococcus aureus is added and static culture is performed at 37 ° C. After culturing, the turbidity of the test tube was observed to determine whether it had an antibacterial activity.

(参考資料 CHEMOTHERAPY Jan.1981.Vo129.No1.76〜7
9) 2.リパーゼ活性阻害試験 基質としてオリーブ油を用い、リパーゼ及び試料を添
加して、リパーゼ作用によって遊離した脂肪酸をアルカ
リ滴定して定量し、コントロールとの比較によってリパ
ーゼ活性阻害効果を測定した。(酵素利用ハンドブッ
ク.地人書館.小崎道雄.230〜233) 3.ヒスタミン遊離抑制試験 ラットより取り出し分離した肥満細胞を用いて、試
料,肥満細胞及びヒスタミン遊離物質を混合して肥満細
胞より遊離されるヒスタミンを定量し、コントロールと
の比較によってヒスタミン遊離抑制効果を測定した。ヒ
スタミン遊離物質としては、コンカナバリンA(以後Co
n.A)とコウパウンド48/80(以後Comp.48/80)を用い
た。
(Reference material CHEMOTHERAPY Jan.1981.Vo129.No1.76 ~ 7
9) 2. Lipase activity inhibition test Using olive oil as a substrate, lipase and a sample were added, and fatty acids liberated by the lipase action were quantified by alkali titration, and the lipase activity inhibition effect was measured by comparison with a control. (Handbook of Enzyme Use. Chijin Shokan. Michio Kozaki. 230-233) 3. Histamine Release Inhibition Test Using mast cells taken out from the rat, the sample, mast cells and histamine releasing substance are mixed and released from mast cells. Histamine was quantified and the histamine release inhibitory effect was measured by comparison with a control. Concanavalin A (hereinafter Co
nA) and Ko pound 48/80 (hereinafter Comp.48 / 80) were used.

(生薬学雑誌.37(4).374〜380.1983) 4.抗酸化試験 リノール酸の自由酸化により、生成する過酸化物によ
ってFe2+がFe+3になる。これがNH4SCNと反応して赤色の
ロダン鉄Fe(SCN)を生成するので、その吸光度から
過酸化物の量を測定した。
(Biopharmaceutical magazine. 37 (4) .374-380.1983) 4. Antioxidant test Fe 2+ becomes Fe +3 due to the peroxide generated by free oxidation of linoleic acid. Since this reacts with NH 4 SCN to produce red rhodanic iron Fe (SCN) 3 , the amount of peroxide was measured from its absorbance.

(Agric Biol.Chem.45(3).735〜739.1981) 表1(実施例1〜3)及び表2(比較例1〜3)の化
粧水の製造方法は表1,2に示す配合組成で、1のエタノ
ールに2〜5と9(BHT)を溶解したものと10の精製水
に6〜8を溶解したものを混合し化粧水を得た。
(Agric Biol. Chem. 45 (3) .735-739.1981) The method for producing the lotion of Table 1 (Examples 1 to 3) and Table 2 (Comparative Examples 1 to 3) has the composition shown in Tables 1 and 2. Toner lotion was obtained by mixing 2 to 5 and 9 (BHT) dissolved in 1 ethanol and 6 purified water dissolved in 10 purified water.

表3は、表1(実施例1〜3)と表2(比較例1〜
3)について、抗酸化試験を行った結果を示したもので
ある。実施例1〜3は、抗酸化剤としてよく知られてい
るBHTを配合した比較例3と比べても、時間的な吸光度
変化であまり差はなく、実施例1〜3は抗酸化作用があ
ることがわかる。実施例1〜3に比べて、カリミョウバ
ン抜きの比較例1,酸抜きの比較例2は、抗酸化作用がほ
とんどないことがわかる。
Table 3 shows Table 1 (Examples 1 to 3) and Table 2 (Comparative Examples 1 to 1).
Regarding 3), the results of an antioxidant test are shown. Examples 1 to 3 have little difference in the absorbance change with time even compared with Comparative Example 3 containing BHT which is well known as an antioxidant, and Examples 1 to 3 have an antioxidant action. I understand. As compared with Examples 1 to 3, Comparative Example 1 without potassium alum and Comparative Example 2 without acid have almost no antioxidant effect.

表4は、表1(実施例1〜3)と表2(比較例1〜
2)についてリパーゼ活性阻害試験を行った結果を示し
た。実施例1〜3のリパーゼ活性阻害率は、50%以上で
ありかなり高い効果があることがわかる。これと比べ
て、比較例1〜2のリパーゼ活性阻害率は、6%以下で
効果がほとんどないことがわかる。
Table 4 shows Table 1 (Examples 1 to 3) and Table 2 (Comparative Examples 1 to 1).
The results of the lipase activity inhibition test for 2) are shown. The lipase activity inhibition rate of Examples 1 to 3 is 50% or more, which shows that the effect is considerably high. In comparison with this, it can be seen that Comparative Examples 1 and 2 have almost no effect when the lipase activity inhibition rate is 6% or less.

表5の乳液の製造方法としては、油相(1〜6のも
の)を70℃で加熱溶解し、その中に予め7に8〜12を加
熱溶解し70℃まで加温したものは攪はんしながら添加し
乳化する。これを30℃まで冷却して乳液を得た。
As the method for producing the emulsion of Table 5, the oil phase (those of 1 to 6) is heated and dissolved at 70 ° C, and 8 to 12 of 7 is heated and dissolved in advance and heated to 70 ° C. While adding, emulsify. This was cooled to 30 ° C. to obtain an emulsion.

表6,7は、表5(実施例4,5と比較例4,5)について、
P.acnes菌と黄色ブドウ球菌に対する抗菌力試験を行っ
た結果を示す。この結果より、実施例4,5は、いずれも
試料濃度70%以上でP.acnes菌及び黄色ブドウ球菌に対
して抗菌力を示した。しかし比較例4,5は、いずれの試
料濃度でもP.acnes菌及び黄色ブドウ球菌に対して抗菌
性を示さなかった。
Tables 6 and 7 are for Table 5 (Examples 4 and 5 and Comparative Examples 4 and 5).
The result of having carried out the antibacterial activity test with respect to P.acnes bacteria and Staphylococcus aureus is shown. From these results, all of Examples 4 and 5 showed antibacterial activity against P. acnes and Staphylococcus aureus at a sample concentration of 70% or more. However, Comparative Examples 4 and 5 did not show antibacterial activity against P. acnes and Staphylococcus aureus at any sample concentration.

表8は、表5(実施例4,5と比較例4,5)について、ヒ
スタミン遊離抑制効果を測定した。実施例4,5は、ヒス
タミン遊離物質Con.A及びComp.48/80いずれの場合でも
ヒスタミン遊離抑制率が、90%以上で効果が高かった。
しかし比較例4,5では、いずれも6%以下でヒスタミン
遊離抑制効果はなかった。
Table 8 shows the histamine release inhibiting effect of Table 5 (Examples 4 and 5 and Comparative Examples 4 and 5). In Examples 4 and 5, the histamine release inhibiting rate was 90% or more and the effect was high in both cases of the histamine releasing substance Con.A and Comp.48 / 80.
However, in Comparative Examples 4 and 5, the histamine release inhibiting effect was 6% or less in all cases.

表9のクリームの製造方法は、表5の乳液と同様の方
法で、油相(1〜5のもの)を70℃で加熱溶解し、予め
70℃に加熱溶解した水相(6〜11のもの)を油相に攪は
んしながら添加し乳化する。これを30℃まで冷却してク
リームを得た。
The manufacturing method of the cream of Table 9 is the same method as the emulsion of Table 5, and the oil phase (1-5) is heated and dissolved at 70 ° C.
The aqueous phase (6-11) heated and dissolved at 70 ° C. is added to the oil phase with stirring to emulsify. This was cooled to 30 ° C. to obtain a cream.

表10は、表9(実施例6,7と比較例6,7)の使用試験を
行った結果を示したものである。被験者は吹出物で悩ん
でいる人、使用期間は2週間使用してもらい、使用前後
での吹出物にへの効果をみた。吹出物に対する効果は、
表10に下記した方法で評価した。この結果から、実施例
6,7は吹出物に対してかなり高い効果があることがわか
る。
Table 10 shows the results of the use tests of Table 9 (Examples 6 and 7 and Comparative Examples 6 and 7). The test subject was a person who suffered from pimples, and had them be used for 2 weeks, and the effect on the pimples before and after use was observed. The effect on pimples is
The evaluation was carried out by the method shown in Table 10 below. From this result,
It can be seen that 6,7 has a considerably high effect on the pimples.

試料濃度とは、抗菌力試験の操作中での試料と蒸留水
の割合である。例えば、試験濃度60%は、試料と蒸留水
の比率が6:4で混合し測定したものである。
The sample concentration is the ratio of the sample and distilled water during the operation of the antibacterial activity test. For example, a test concentration of 60% is measured by mixing the sample and distilled water at a ratio of 6: 4.

フロントページの続き (72)発明者 小林 利行 愛知県名古屋市西区鳥見町2丁目130番 地 日本メナード化粧品株式会社中央研 究所内 (72)発明者 中平 盟 愛知県名古屋市西区鳥見町2丁目130番 地 日本メナード化粧品株式会社中央研 究所内 (72)発明者 中田 悟 愛知県名古屋市西区鳥見町2丁目130番 地 日本メナード化粧品株式会社中央研 究所内 (72)発明者 小西 宏明 愛知県名古屋市西区鳥見町2丁目130番 地 日本メナード化粧品株式会社中央研 究所内 (56)参考文献 特開 昭48−5023(JP,A) 特開 昭48−23908(JP,A) 特開 昭59−62516(JP,A)Front page continuation (72) Inventor Toshiyuki Kobayashi 2-130, Torimi-cho, Nishi-ku, Nagoya-shi, Aichi Nihon Menard Cosmetics Co., Ltd. Central Research Laboratory (72) Inventor Nakahira 2-130, Torimi-cho, Nishi-ku, Nagoya-shi, Aichi Address Japan Menard Cosmetics Co., Ltd. Central Research Laboratory (72) Inventor Satoru Nakata 2-130 Torimicho, Nishi-ku, Aichi Prefecture Nagoya City Central Research Laboratory (72) Inventor Hiroaki Konishi Nagoya City, Aichi Prefecture 2-130 Torimi-cho, Nishi-ku, Japan, Central Research Institute, Menard Cosmetics Co., Ltd. (56) References JP-A-48-5023 (JP, A) JP-A-48-23908 (JP, A) JP-A-59-62516 (JP, A)

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】カリミョウバンと,マロン酸,クエン酸,
ショウ酸,コハク酸,フマル酸,リンゴ酸,酒石酸,ピ
ロリドンカルボン酸,アスパラギン酸,及びグルタミン
酸のグループから選ばれる1種又は2種以上からなる酸
とを配合してなり, かつ抗菌力,リパーゼ活性阻害,ヒスタミン遊離抑制,
及び抗酸化力を有することを特徴とする抗炎症効果を有
する化粧料。
1. Alum and malonic acid, citric acid,
A mixture of one or more acids selected from the group consisting of oxalic acid, succinic acid, fumaric acid, malic acid, tartaric acid, pyrrolidonecarboxylic acid, aspartic acid, and glutamic acid, and having antibacterial activity and lipase activity. Inhibition, histamine release inhibition,
And a cosmetic having an anti-inflammatory effect, which has an antioxidative power.
JP63265034A 1988-10-20 1988-10-20 Cosmetics Expired - Lifetime JP2530488B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP63265034A JP2530488B2 (en) 1988-10-20 1988-10-20 Cosmetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63265034A JP2530488B2 (en) 1988-10-20 1988-10-20 Cosmetics

Publications (2)

Publication Number Publication Date
JPH02111714A JPH02111714A (en) 1990-04-24
JP2530488B2 true JP2530488B2 (en) 1996-09-04

Family

ID=17411669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63265034A Expired - Lifetime JP2530488B2 (en) 1988-10-20 1988-10-20 Cosmetics

Country Status (1)

Country Link
JP (1) JP2530488B2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2715066A1 (en) * 1994-01-17 1995-07-21 Dargoire Laboratoire Philippe Soap holder with permeable plate in contact with soap
FR2728793A1 (en) * 1994-12-28 1996-07-05 Oreal Compsns. for treating sensitive skin
KR19990048303A (en) * 1997-12-09 1999-07-05 성재갑 Cosmetic soap composition
FR2781149B1 (en) * 1998-07-17 2001-09-07 Oreal DEODORANT COMPOSITION CONTAINING ALUM SALT
JP2002326942A (en) * 2001-05-07 2002-11-15 Nonogawa Shoji Kk Preparation for external use for skin
JP3935441B2 (en) * 2003-01-20 2007-06-20 日本メナード化粧品株式会社 Bath salt composition
KR100863617B1 (en) * 2007-04-19 2008-10-15 바이오스펙트럼 주식회사 Compositions for improving skin conditions comprising alum
TR200805017A2 (en) * 2008-07-07 2008-11-21 Kazim Özgüven Yi̇ği̇t Dermatological composition for use in the treatment and / or prevention of skin diseases
AT513523A1 (en) * 2012-11-06 2014-05-15 Gl & Partners Og Treatment of skin diseases
JP6840324B2 (en) * 2017-03-13 2021-03-10 日本メナード化粧品株式会社 Topical skin for acne prevention and / or improvement
KR102104214B1 (en) * 2019-12-24 2020-04-23 오한상 Cosmetic composition comprising potassium alum

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2524310A2 (en) * 1982-04-01 1983-10-07 Olivier Georges COMPOSITIONS FOR COMBATTING MEASURES AND DISADVANTAGES OF PERSPIRATION

Also Published As

Publication number Publication date
JPH02111714A (en) 1990-04-24

Similar Documents

Publication Publication Date Title
JP2530488B2 (en) Cosmetics
JPH08500831A (en) Deodorant cosmetic composition having fatty acid content
JPS63192703A (en) External agent for skin
JP2007022923A (en) Hair follicle apoptosis reaction inhibitor and hair cosmetic composition
JP2005200370A (en) Nitrogen monoxide production promotor and its utilization
JP2019014765A (en) Antimicrobial compositions and production methods thereof
US6019989A (en) Skin activator with glycosaminoglycan production-accelerating effect
JP4681132B2 (en) Nitric oxide synthase production promoter and cosmetic or pharmaceutical composition
JPH07194375A (en) Promoter for synthesizing collagen and collagen metabolism activator
JPH10182411A (en) Preparation for external use for skin
WO2017034005A1 (en) Method for preparing high-water-content emulsion gel using oil gel-forming agent
EP2787050A1 (en) Lecithin-organogel-forming agent
JPH0867621A (en) Skin activator having glycosaminoglycan production-accelerating action
JP2003231626A (en) Atp production promoter
JP2013010693A (en) Mitf-m production promoter, and hair cosmetic composition and skin cosmetic composition comprising the mitf-m production promoter
JP2000327525A (en) Skin preparation for external use
JP3262780B2 (en) Phytosphingosine aqueous solution, its production and use
JP5154780B2 (en) Nitric oxide production promoter and use thereof
JP2006256976A (en) Agent for hair growth and restoration and method for hair growth and restoration
JP2589761B2 (en) Cosmetic additives
JPH04187618A (en) Skin external preparation
JP2020169128A (en) Hair cleanser composition
CN109498509A (en) A kind of stoste and preparation method thereof with a variety of skin effects
JP3431913B2 (en) Vascular endothelial cell growth factor production promoter and skin color improving agent
JP2003089635A (en) Antibacterial composition, cosmetic and skin care lotion

Legal Events

Date Code Title Description
S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090614

Year of fee payment: 13